🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — July 09, 2026

The 19 filings reveal a sharply bifurcated earnings landscape. While large-cap consumer staples (PepsiCo) and select industrials (EACO, Enerpac) posted strong revenue and profit growth, the broader picture is one of distress across small-cap and growth names. A cluster of companies (KB Home, Byrna Technologies, Simply Good Foods, Nurix Therapeutics) reported severe profit declines or swings to losses, driven by demand drops, inventory write-downs, and impairment charges. Cash burn is a dominant theme, with several micro-cap firms (IIOT-OXYS, MADE IN USA, WidFit) showing zero or declining cash positions and negative working capital. Insider activity was sparse, but the aggressive share repurchases at Jefferies ($372M) and Simply Good Foods ($213M) signal management confidence at those firms. The most critical development is the collapse in gross margins at Byrna Technologies (from 61.6% to 10.9%) and the 74.6% net income drop at KB Home, which point to potential sector-specific headwinds in consumer durables and non-lethal defense. Portfolio-level patterns include a 'growth at any cost' theme in biotech (Nurix) and a 'profitless growth' theme in several small industrials (NTIC, Medinotec).

19 high priority 19 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 09, 2026

This digest covers 10 proxy filings, with a dominant theme of corporate control events: four companies (Leggett & Platt, LivePerson, RE/MAX, EBR Systems) are pursuing transformative M&A, while two (Ascend Wellness, RYTHM) seek shareholder approval for capital structure changes. Executive compensation trends show significant compression at TuHURA Biosciences (CEO pay down 34% YoY, CFO down 37%), reflecting post-merger cost discipline. Insider activity is notably absent across most filings, but the heavy M&A pipeline creates binary risk/reward profiles. The most actionable signals come from the acquisition arbitrage opportunities in LivePerson (22% premium, collar structure) and RE/MAX (fixed exchange ratio with declining implied value), while governance concerns at TuHURA (infrequent committee meetings, late insider filings) and InnSuites (non-independent trustees) warrant monitoring. The fund repositioning at New York Life Investments offers a unique catalyst for international equity exposure.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 09, 2026

The July 9, 2026, IPO pipeline is dominated by a mix of traditional SPAC, development-stage, and distressed issuers, alongside a major M&A-driven registration from NextEra Energy. The most significant theme is the surge in capital markets activity tied to transformative M&A, with the NextEra-Dominion S-4 representing a $60B+ implied deal and the Pulmatrix-Eos merger targeting a high-risk biotech combination. On the IPO front, Southern Cross Acquisition II (SPAC) and Leef Brands (cannabis) provide contrasting risk profiles, while Mitesco and Jaovi represent deeply distressed or micro-cap filings with going-concern warnings. Period-over-period data reveals mixed revenue trends: Leef Brands grew 15% YoY but with uneven segment performance, while Pulmatrix showed a 15% revenue increase but widening losses. The absence of insider trading activity in most filings is notable, though the Mitesco filing implies significant insider dilution via debt conversion. Overall, the pipeline signals a bifurcated market where quality issuers (NextEra) use registered exchanges for debt, while speculative and distressed entities test the IPO window.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — July 09, 2026

All four filings in this digest highlight micro-cap companies facing imminent delisting or trading suspension from US exchanges (NASDAQ and NYSE American), driven by non-compliance with minimum bid price and shareholders' equity requirements. The cluster of events on July 2-9, 2026, signals a potential sector-wide liquidity and valuation crisis among small-cap issuers, with no positive period-over-period trends or insider buying to offset the negative outlook. The most critical development is the immediate delisting risk for Prairie Operating Co. if its stock trades at or below $0.10 for ten consecutive days, representing a binary event. Across the portfolio, all companies are in the 'cure period' with no forward-looking guidance or capital allocation improvements, suggesting a high probability of eventual suspension or delisting. The aggregate market implication is a bearish signal for micro-cap equities, as regulatory enforcement appears to be tightening on chronically non-compliant issuers.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 09, 2026

This digest covers 25 filings from July 9, 2026, focused on executive and director changes. A clear theme is the strategic appointment of seasoned leaders from top-tier firms (Apple, Disney+, NetApp) to drive growth and operational scaling, particularly in the technology and energy sectors. Period-over-period data from Enovix and Pure Cycle shows strong revenue growth (49% and 60% YoY, respectively), but also highlights ongoing challenges like margin pressure and regulatory uncertainty. Notable insider activity includes a significant CEO transition at FuboTV and a shareholder activist resolution at Central Plains Bancshares. The most critical developments are the high-profile CEO appointment at FuboTV, the CFO transition at Philip Morris, and the operational leadership changes at Enovix and SoCalGas, all of which have clear market implications for their respective sectors. Portfolio-level patterns reveal a focus on internal promotions for CFO roles and a trend of appointing directors with deep industry or scientific expertise.

25 high priority 25 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 09, 2026

The 25 filings reveal a significant wave of C-suite and board-level transitions across US-listed companies, with a notable concentration of CFO and COO changes, often tied to strategic pivots or operational scaling. Key period-over-period trends are limited but include Enovix's 49% YoY revenue growth and Pure Cycle's 60% YoY revenue surge, both linked to new leadership appointments aimed at accelerating manufacturing and land development. The most critical developments include the appointment of a former Disney+ president as CEO of FuboTV, signaling a strategic shift in the streaming space, and a shareholder activist-driven board appointment at Central Plains Bancshares, highlighting governance pressure in small-cap financials. Portfolio-level patterns indicate a focus on operational execution and commercial capability building, with several companies (UNFI, Enovix, SoCalGas) bringing in seasoned operators to drive growth. Insider activity is sparse, but the lack of insider selling in most transitions suggests orderly successions, though the departure of a 23-year veteran at UNFI and a key legal officer at Align Technology introduce execution risk.

25 high priority 25 total filings
· daily

USA Insider Trading Pulse — July 09, 2026

The July 9, 2026 insider trading pulse reveals a stark divergence in management conviction across sectors. The dominant theme is a massive, coordinated insider buying wave at Taiwan Semiconductor Manufacturing Co (TSMC), where 26 executives, including the Chairman/CEO, collectively purchased shares at $76.62, signaling extreme confidence in the company's near-term prospects. In sharp contrast, the healthcare and technology sectors show a pattern of high-level insider selling, with CEOs at ResMed, Pennant Group, and Ceribell executing significant sales under 10b5-1 plans, suggesting a desire to lock in gains. Financial insiders present a mixed picture, with some executives selling small lots while others are awarded shares. A notable positive signal comes from a 10% owner at AMG BBH Asset-Backed Credit Fund, who made a substantial $457K purchase. The overall portfolio-level trend points to a strong vote of confidence in semiconductor manufacturing, while caution flags are raised in healthcare and select financials, where insider selling is more prevalent.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 09, 2026

The July 9, 2026 M&A digest reveals a market bifurcated between high-conviction, strategic acquisitions (T3 Defense's purchase of Project 35, IKS Health's acquisition of TruBridge, MARA's land deal) and a wave of SPACs struggling to complete deals or facing existential deadlines. A clear theme is the capital-intensive pivot toward defense tech and digital infrastructure, with two major transactions totaling over $300M in implied value. Conversely, the SPAC market shows acute distress: Bayview Acquisition Corp faces Nasdaq delisting after a failed merger, while byNordic and Plum are burning through final extensions with high redemption risks. Period-over-period data from the enriched filings shows zero insider buying across all SPACs, contrasting with strong management conviction in the operating companies. The most actionable insight is the divergence between well-capitalized acquirers executing on strategy and SPACs with deteriorating timelines and no targets, creating both risk and opportunity for event-driven investors.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 09, 2026

Overnight filings reveal a mixed picture for US markets, with a notable cluster of insider selling at high-profile growth companies (Warby Parker, Airbnb, CrowdStrike) and a major deal collapse in the media sector (Shutterstock/Getty Images). The most significant positive signal is a broad-based equity grant program at General Mills, indicating strong long-term incentive alignment across its leadership team. A key risk theme emerges from the pledging of a large block of Applied Digital shares against a margin loan, creating potential for forced selling. On the turnaround front, Huineng Technology reported a dramatic swing to profitability, while ENDRA Life Sciences regained Nasdaq compliance, removing a near-term delisting risk. The overall tone is cautious, with insider selling outweighing buying, but the General Mills grants and the Cellectar Biosciences option awards suggest confidence in future growth at specific companies.

45 high priority 5 medium 50 total filings
· daily

DHS Homeland Security Contracts — July 08, 2026

Over a single day, the Department of Homeland Security awarded $480.3 million in contracts, all civilian, with an average signal strength of 5.2/10. The dominant theme is DHS/ICE spending on IT, cyber, and healthcare support services, accounting for four of the five awards. The highest-conviction signal is TRM LABS, INC.'s $94.7 million sole-source award for cyber analytical support, indicating a unique capability or urgent need, but its non-competitive structure and single-year term introduce execution risk. A key risk is the concentration of awards to ICE, which faces political and budgetary uncertainty that could impact contract performance and option exercises.

5 total filings
· daily

VA Healthcare & Services Contracts — July 08, 2026

The single contract digest for July 8, 2026, covers a $81.3 million modification awarded to TISTA SCIENCE AND TECHNOLOGY CORPORATION by the Department of Veterans Affairs, representing a purely civilian healthcare and services stream with no defense exposure. The contract carries a neutral signal with medium confidence, as key details on pricing, competition, and revenue impact are unknown, limiting actionable conviction. The dominant theme is VA healthcare IT or services spending, but the lack of competitive context or performance risk data makes this a watch-and-confirm item rather than a clear catalyst. Key risk is the absence of transparency on whether this is a sole-source or competed award, which could imply either a strong incumbent position or a protest-vulnerable non-competitive award.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 08, 2026

This digest covers a single $77.6M civilian contract awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., by the NIH National Cancer Institute (NCI). The contract is a cost-plus-fixed-fee delivery order for operational tasks, with options that could bring the total to $139.9M through August 2027. The award reinforces Leidos’s stable position in federal health R&D services, a sector with sustained funding from NIH. The neutral signal (strength 5/10, materiality 4/10) reflects moderate size and low risk, with no bullish or bearish catalysts. Key watch items include option year exercise by August 2026 and any modifications to the task order.

1 total filings
· daily

New Federal Contractors — July 08, 2026

This digest of 13 new federal contracts, totaling $1.16 billion in obligations, is overwhelmingly civilian (12 of 13 awards), with the Department of Homeland Security (DHS) as the dominant agency, accounting for five awards worth $447 million. The Department of Health and Human Services (HHS) is the second-largest spender, with three awards totaling $250 million. The highest-conviction signals are two bullish contracts: Deloitte & Touche LLP's $86.1 million HHS identity management win and ESIMPLICITY Inc's $80.1 million CMS data systems award, both reflecting competitive wins in stable, mandated IT programs. A key risk is the concentration of DHS awards to small or niche firms (TRM LABS, INSERSO, Amergis), which introduces execution and protest vulnerability, while the sole-source, fixed-price $94.7 million award to TRM LABS carries high execution risk. There is no defense-sector exposure in this batch, limiting actionable signals for defense-focused investors.

13 total filings
· daily

Biotech Small-Cap Approvals — July 08, 2026

The July 8, 2026, small-cap biotech approval stream delivered five biosimilar/other approvals with zero NMEs, zero label expansions, and zero biosimilar designations, resulting in a uniformly neutral signal set. The dominant theme is generic/biosimilar market expansion across diverse therapeutic areas—metabolic (liraglutide), neurology (brivaracetam), cardiovascular (chlorthalidone), and ophthalmology (brimonidine tartrate)—with no single therapeutic cluster emerging as a sector signal. The highest-conviction event is SANDOZ’s approval for liraglutide, which signals incremental competitive pressure on the GLP-1 class, though without disclosed sales estimates or exclusivity details, commercial impact remains unquantifiable. Key risk: the absence of any NME or breakthrough therapy approvals in this period highlights a lack of high-value innovation catalysts for small-cap sponsors, reinforcing a cautious near-term outlook for the sub-sector.

5 total filings
· daily

Significant Contract Modifications ($10M+) — July 08, 2026

This digest of 13 government contracts, totaling $1.16 billion in obligations from July 8, 2026, reveals a heavily civilian-dominated procurement landscape, with only one defense-related award. The Department of Homeland Security (DHS) is the dominant spender, accounting for five contracts worth $447.5 million, led by TSA baggage screening and ICE detention medical and cyber support. The highest-conviction signal is the $94.7 million sole-source award to TRM LABS, INC. for DHS cyber disruption support, indicating urgent, non-competitive demand for specialized cyber analytics. A key risk is the high execution risk on TRM LABS' fixed-price, one-year contract, which could pressure margins for this small business. Overall, the digest signals stable civilian agency spending on IT, security, and healthcare staffing, with limited direct defense sector exposure.

13 total filings
· daily

New Drug Approvals (Original) — July 08, 2026

The July 8, 2026, FDA approval digest is dominated by five biosimilar/other approvals, with zero NMEs, zero label expansions, and zero biosimilars (as classified by the stream), resulting in a neutral signal across the board. The period lacks high-conviction catalysts, as all approvals are FALLBACK-type generics or biosimilar equivalents for established molecules: LEVOCARNITINE (Baxter Healthcare), BRIVARACETAM (ScieGen Pharms), CHLORTHALIDONE (Macleods Pharma), BRIMONIDINE TARTRATE (Saba Ilac Sanayi), and LIRAGLUTIDE (Sandoz). The most notable commercial signal is Sandoz’s approval for LIRAGLUTIDE, which enters the high-value GLP-1 biosimilar market, posing a bearish risk to Novo Nordisk’s originator franchise (Victoza/Saxenda). The key risk is that these are low-materiality, non-innovative approvals with no disclosed peak sales estimates, offering limited differentiation for investors. No IRA exposure flags are triggered as all are off-patent generics or biosimilars with no remaining exclusivity.

5 total filings
· daily

Contract Deobligations Alert — July 08, 2026

This digest of 13 government contract obligations totaling $1.16 billion reveals a civilian-agency-dominated procurement environment, with only 1 of 13 awards defense-related (DHS/TSA). The dominant sector theme is federal IT and healthcare services, led by DHS (5 contracts, $407M aggregate) and HHS (4 contracts, $328M aggregate). The highest-conviction signal is the $94.7M sole-source cyber support award to TRM LABS, INC. by DHS/ICE, indicating urgent capability needs. Key risks include concentration in civilian agency budgets vulnerable to Continuing Resolution uncertainty and execution risk on fixed-price contracts like BAE Systems' $97.6M FEMA IT award where only 38% of funds are outlayed. The aggregate signal strength of 5.4/10 reflects a neutral-to-mildly-bullish tone with no bearish signals identified, but investors should monitor re-compete dates and option exercises for revenue visibility.

13 total filings
· daily

Contract Option Exercises — July 08, 2026

This digest covers 13 contract option exercises totaling $1.159 billion, with only 1 defense-related award (8% of total value) and the remainder concentrated in civilian agencies, primarily DHS ($380M across 4 contracts) and HHS ($328M across 4 contracts). The dominant theme is sustained civilian IT and healthcare services spending, with notable sole-source awards to TRM LABS ($94.7M) and The Aerospace Corporation ($141.2M) signaling niche capabilities. The highest-conviction signal is the bullish competitive win for Deloitte ($86.1M obligated) in HHS identity management, while the key risk is the non-competitive, fixed-price award to TRM LABS, which carries high execution risk for a small business. Investors should monitor DHS/ICE detention healthcare spending (Amergis, $97.4M) and the re-compete of Booz Allen’s CMS cloud contract (July 2026).

13 total filings
· daily

Federal Professional Services Contracts — July 08, 2026

The sole contract in this digest, a $126.2 million firm-fixed-price delivery order awarded to VERTEX AEROSPACE LLC by the Transportation Security Administration (DHS), represents a pure civilian agency security infrastructure play with zero defense exposure. The contract is for Checked Baggage Inspection System (CBIS) remediation, a security-critical program with $106.4 million already outlayed, signaling high execution certainty and a stable multi-year revenue stream for VERTEX through July 2026. The neutral signal strength (6/10) reflects the moderate risk of a fixed-price structure and full-and-open competition, balanced against the long-term visibility and sustained demand from TSA's aviation security priorities. Key risks include potential budget reallocations within DHS and the absence of a competitive moat signal, as the award was competitively won.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 08, 2026

This digest covers $556.8 million in federal IT and cybersecurity contracts awarded between 2022 and 2026, with zero defense-related awards, underscoring a purely civilian procurement focus. The dominant theme is health IT modernization, driven by the Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS), which account for $250.2 million (45%) of total obligation across three contracts to Deloitte, Booz Allen Hamilton, and ESIMPLICITY. The highest-conviction signal is Deloitte's $86.1 million HSPD-12 identity management win, a competitive award with strong funding commitment ($65M outlaid) and sustained demand from a mandated program. A key risk is the concentration of awards among small businesses (TRM LABS, TISTA, ESIMPLICITY, INSERSO) that face execution risk on fixed-price or time-and-materials contracts, particularly TRM LABS' $94.7 million sole-source award with high pricing risk.

7 total filings